Identification of potential crucial genes associated with the pathogenesis and prognosis of pancreatic adenocarcinoma

Shi,Lan-Er; Shi,Lan-Er; Shi,Lan-Er; Shi,Lan-Er; Shi,Lan-Er; Shi,Lan-Er; Shang,Xin; Shang,Xin; Shang,Xin; Shang,Xin; Shang,Xin; Shang,Xin; Nie,Ke-Chao; Nie,Ke-Chao; Nie,Ke-Chao; Nie,Ke-Chao; Nie,Ke-Chao; Nie,Ke-Chao; Xu,Qiang; Xu,Qiang; Xu,Qiang; Xu,Qiang; Xu,Qiang; Xu,Qiang; Chen,Na-Bei; Chen,Na-Bei; Chen,Na-Bei; Chen,Na-Bei; Chen,Na-Bei; Chen,Na-Bei; Zhu,Zhang-Zhi; Zhu,Zhang-Zhi; Zhu,Zhang-Zhi; Zhu,Zhang-Zhi; Zhu,Zhang-Zhi; Zhu,Zhang-Zhi

doi:10.3892/ol.2020.11921

Identification of potential crucial genes associated with the pathogenesis and prognosis of pancreatic adenocarcinoma

Authors:
- Lan-Er Shi
- Xin Shang
- Ke-Chao Nie
- Qiang Xu
- Na-Bei Chen
- Zhang-Zhi Zhu
View Affiliations

Affiliations: Department of Endocrinology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China
Published online on: July 29, 2020 https://doi.org/10.3892/ol.2020.11921
Article Number: 60
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic adenocarcinoma (PAAD) is a type of malignant tumor with the highest mortality rate among all neoplasms worldwide, and its exact pathogenesis is still poorly understood. Timely diagnosis and treatment are of great importance in order to decrease the mortality rate of PAAD. Therefore, identifying new biomarkers for diagnosis and prognosis is essential to enable early detection of PAAD and to improve the overall survival (OS) rate. In order to screen and integrate differentially expressed genes (DEGs) between PAAD and normal tissues, a total of seven datasets were downloaded from the Gene Expression Omnibus database and the ‘limma’ and ‘robustrankggreg’ packages in R software were used. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis of the DEGs was performed using the Database for Annotation, Visualization and Integrated Discovery website, and the protein‑protein interaction network analysis was performed using the Search Tool for the Retrieval of Interacting Genes/Proteins database. A gene prognostic signature was constructed using the Cox regression model. A total of 10 genes (CDK1, CCNB1, CDC20, ASPM, UBE2C, TPX2, TOP2A, NUSAP1, KIF20A and DLGAP5) that may be associated with pancreatic adenocarcinoma were identified. According to the differentially expressed genes in The Cancer Genome Atlas, the present study set up four prognostic signatures (matrix metalloproteinase 12, sodium voltage‑gated channel α subunit 11, tetraspanin 1 and SH3 domain and tetratricopeptide repeats‑containing 2), which effectively predicted OS. The hub genes that were highly associated with the occurrence, development and prognosis of PAAD were identified, which may be helpful to further understand the molecular basis of pancreatic cancer and guide the synthesis of drugs for PPAD.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Gordon-Dseagu VL, Devesa SS, Goggins M and Stolzenberg-Solomon R: Pancreatic cancer incidence trends: Evidence from the surveillance, epidemiology and end results (SEER) population-based data. Int J Epidemiol. 47:427–439. 2018. View Article : Google Scholar : PubMed/NCBI
3	Golan T, Sella T, Margalit O, Amit U, Halpern N, Aderka D, Shacham-Shmueli E, Urban D and Lawrence YR: Short- and long-term survival in metastatic pancreatic adenocarcinoma, 1993-2013. J Natl Compr Canc Netw. 15:1022–1027. 2017. View Article : Google Scholar : PubMed/NCBI
4	Mackay MT, van Erning FN, van der Geest LG, Koerkamp BG, van Laarhoven MH, Bonsing BA, Wilmink JW, van Santvoort HC, de Vos-Geelen Jd, van Eijck CH, et al: Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: A population-based analysis. Pancreatology. 18 (Suppl):S1322018. View Article : Google Scholar
5	Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, de Hingh IHJT, de Meijer VE, Molenaar IQ, van Santvoort HC, van Tienhoven G, et al: Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 125:83–93. 2020. View Article : Google Scholar : PubMed/NCBI
6	Mokdad AA, Minter RM, Yopp AC, Porembka MR, Wang SC, Zhu H, Augustine MM, Mansour JC, Choti MA and Polanco PM: Comparison of overall survival between preoperative chemotherapy and chemoradiotherapy for resectable pancreatic adenocarcinoma. J Natl Compr Canc Netw. 16:1468–1475. 2018. View Article : Google Scholar : PubMed/NCBI
7	Moore MJ and Stathis A: Advanced pancreatic carcinoma: Current treatment and future challenges. Nat Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jun I, Park HS, Piao H, Han JW, An MJ, Yun BG, Zhang X, Cha YH, Shin YK, Yook JI, et al: ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. Br J Cancer. 117:1798–1809. 2017. View Article : Google Scholar : PubMed/NCBI
9	Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Öhlund D, et al: NRF2 promotes tumor maintenance by modulating mrna translation in pancreatic cancer. Cell. 166:963–976. 2016. View Article : Google Scholar : PubMed/NCBI
10	Jain A, Brown SZ, Thomsett HL, Londin E and Brody JR: Evaluation of post-transcriptional gene regulation in pancreatic cancer cells: Studying RNA binding proteins and their mRNA targets. Methods Mol Biol. 1882:239–252. 2019. View Article : Google Scholar : PubMed/NCBI
11	Uchida S, Kinoh H, Ishii T, Matsui A, Tockary TA, Takeda KM, Uchida H, Osada K, Itaka K and Kataoka K: Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials. 82:221–228. 2016. View Article : Google Scholar : PubMed/NCBI
12	Hutter C and Zenklusen JC: The cancer genome atlas: Creating lasting value beyond its data. Cell. 173:283–285. 2018. View Article : Google Scholar : PubMed/NCBI
13	Ho J, Li X, Zhang L, Liang Y, Hu W, Yau JC, Chan H, Gin T, Chan MT, Tse G and Wu WK: Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset. Semin Cancer Biol. 55:70–77. 2019. View Article : Google Scholar : PubMed/NCBI
14	Barrett T: NCBI GEO: Mining millions of expression profiles-database and tools. Nucleic Acids Res. 33:D562–D566. 2004. View Article : Google Scholar
15	Li C, Zeng X, Yu H, Gu Y and Zhang W: Identification of hub genes with diagnostic values in pancreatic cancer by bioinformatics analyses and supervised learning methods. World J Surg Oncol. 16:2232018. View Article : Google Scholar : PubMed/NCBI
16	Tang H, Wei P, Chang P, Li Y, Yan D, Liu C, Hassan M and Li D: Genetic polymorphisms associated with pancreatic cancer survival: A genome-wide association study. Int J Cancer. 141:678–686. 2017. View Article : Google Scholar : PubMed/NCBI
17	Sivakumar S, de Santiago I, Chlon L and Markowetz F: Master regulators of oncogenic KRAS response in pancreatic cancer: An integrative network biology analysis. PLoS Med. 14:e10022232017. View Article : Google Scholar : PubMed/NCBI
18	Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A and Jacks T: Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 8:10902017. View Article : Google Scholar : PubMed/NCBI
19	Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
20	Badea L, Herlea V, Dima SO, Dumitrascu T and Popescu I: Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 55:2016–2027. 2008.PubMed/NCBI
21	Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects cancer cell response to chemotherapy by negatively regulating akt. Cancer Cell. 16:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, et al: DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One. 7:e315072012. View Article : Google Scholar : PubMed/NCBI
23	Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, Patel SG, Wu N, Hindoyan A, Farrell JJ, et al: Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res. 18:1352–1363. 2012. View Article : Google Scholar : PubMed/NCBI
24	Lunardi S, Jamieson NB, Lim SY, Griffiths KL, Carvalho-Gaspar M, Al-Assar O, Yameen S, Carter RC, McKay CJ, Spoletini G, et al: IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget. 5:11064–11080. 2014. View Article : Google Scholar : PubMed/NCBI
25	Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S and Topal B: Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer. 16:6322016. View Article : Google Scholar : PubMed/NCBI
26	Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, et al: A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res. 76:3838–3850. 2016. View Article : Google Scholar : PubMed/NCBI
27	Nie K, Shi L, Wen Y, Pan J, Li P, Zheng Z and Liu F: Identification of hub genes correlated with the pathogenesis and prognosis of gastric cancer via bioinformatics methods. Minerva Med. 111:213–225. 2020. View Article : Google Scholar : PubMed/NCBI
28	Liu L, Lin J and He H: Identification of potential crucial genes associated with the pathogenesis and prognosis of endometrial cancer. Front Genet. 10:3732019. View Article : Google Scholar : PubMed/NCBI
29	Prevo R, Pirovano G, Puliyadi R, Herbert KJ, Rodriguez-Berriguete G, O'Docherty A, Greaves W, McKenna WG and Higgins GS: CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner. Cell Cycle. 17:1513–1523. 2018. View Article : Google Scholar : PubMed/NCBI
30	Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y and Morgan MA: Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res. 19:4422–4432. 2013. View Article : Google Scholar : PubMed/NCBI
31	Wang Z, Fan M, Candas D, Zhang TQ, Qin L, Eldridge A, Wachsmann-Hogiu S, Ahmed KM, Chromy BA, Nantajit D, et al: Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression. Dev Cell. 29:217–232. 2014. View Article : Google Scholar : PubMed/NCBI
32	Levasseur MD, Thomas C, Davies OR, Higgins JM and Madgwick S: Aneuploidy in oocytes is prevented by sustained CDK1 activity through degron masking in cyclin B1. Dev Cell. 48:672–684. 2019. View Article : Google Scholar : PubMed/NCBI
33	Yu H: Cdc20: A WD40 activator for a cell cycle degradation machine. Mol Cell. 27:3–16. 2007. View Article : Google Scholar : PubMed/NCBI
34	Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C and Wang H: Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol. 5:152012. View Article : Google Scholar : PubMed/NCBI
35	Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, et al: A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Gastroenterology. 145:1110–1120. 2013. View Article : Google Scholar : PubMed/NCBI
36	Hsu CC, Liao WY, Chan TS, Chen WY, Lee CT, Shan YS, Huang PJ, Hou YC, Li CR and Tsai KK: The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis. J Pathol. 249:498–508. 2019. View Article : Google Scholar : PubMed/NCBI
37	Liu G, Zhao J, Pan B, Ma G and Liu L: UBE2C overexpression in melanoma and its essential role in G2/M transition. J Cancer. 10:2176–2184. 2019. View Article : Google Scholar : PubMed/NCBI
38	Jin D, Guo J, Wu Y, Du J, Wang X, An J, Hu B, Kong L, Di W and Wang W: UBE2C, directly targeted by miR-548e-5p, increases the cellular growth and invasive abilities of cancer cells interacting with the EMT marker protein zinc finger E-box binding homeobox 1/2 in NSCLC. Theranostics. 9:2036–2055. 2019. View Article : Google Scholar : PubMed/NCBI
39	Wang X, Yin L, Yang L, Zheng Y, Liu S, Yang J, Cui H and Wang H: Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. FEBS J. 286:4889–4909. 2019. View Article : Google Scholar : PubMed/NCBI
40	Gomes-Filho SM, Dos Santos EO, Bertoldi ER, Scalabrini LC, Heidrich V, Dazzani B, Levantini E, Reis EM and Bassères DS: Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer. Cell Oncol (Dordr). 43:445–460. 2020. View Article : Google Scholar : PubMed/NCBI
41	Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H and Von Hoff DD: Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res. 15:6519–6528. 2009. View Article : Google Scholar : PubMed/NCBI
42	Heestand GM, Schwaederle M, Gatalica Z, Arguello D and Kurzrock R: Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 83:80–87. 2017. View Article : Google Scholar : PubMed/NCBI
43	Pei YF, Yin XM and Liu XQ: TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis. 1864:197–207. 2018. View Article : Google Scholar : PubMed/NCBI
44	Mills CA, Suzuki A, Arceci A, Mo JY, Duncan A, Salmon ED and Emanuele MJ: Nucleolar and spindle-associated protein 1 (NUSAP1) interacts with a SUMO E3 ligase complex during chromosome segregation. J Biol Chem. 292:17178–17189. 2017. View Article : Google Scholar : PubMed/NCBI
45	Garrido-Rodríguez M, Ortea I, Calzado MA, Muñoz E and García V: SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for galiellalactone. J Proteomics. 193:217–229. 2019. View Article : Google Scholar : PubMed/NCBI
46	Taniuchi K, Furihata M and Saibara T: KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells. Neoplasia. 16:1082–1093. 2014. View Article : Google Scholar : PubMed/NCBI
47	Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, et al: Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 104:300–307. 2011. View Article : Google Scholar : PubMed/NCBI
48	Asahara S, Takeda K, Yamao K, Maguchi H and Yamaue H: Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 11:2912013. View Article : Google Scholar : PubMed/NCBI
49	Hewit K, Sandilands E, Martinez RS, James D, Leung HY, Bryant DM, Shanks E and Markert EK: A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor. Cell Death Dis. 19:10692018. View Article : Google Scholar
50	Mello SS, Valente LJ, Raj N, Seoane JA, Flowers BM, McClendon J, Bieging-Rolett KT, Lee J, Ivanochko D, Kozak MM, et al: A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-yap axis in pancreatic cancer. Cancer Cell. 32:460–473. 2017. View Article : Google Scholar : PubMed/NCBI
51	Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, et al: Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell. 35:267–282. 2019. View Article : Google Scholar : PubMed/NCBI
52	Jiang W, Zhao S, Jiang X, Zhang E, Hu G, Hu B, Zheng P, Xiao J, Lu Z, Lu Y, et al: The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett. 371:314–325. 2016. View Article : Google Scholar : PubMed/NCBI
53	Zhang H, Zhang X, Li X, Meng WB, Bai ZT, Rui SZ, Wang ZF, Zhou WC and Jin XD: Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer. J Cell Physiol. 234:619–631. 2019. View Article : Google Scholar
54	Fraser SP, Diss JK, Chioni A, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, et al: Voltage-Gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res. 11:5381–5389. 2005. View Article : Google Scholar : PubMed/NCBI
55	Diss JK, Archer SN, Hirano J, Fraser SP and Djamgoz MB: Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate. 48:165–178. 2001. View Article : Google Scholar : PubMed/NCBI
56	Stellas D and Patsavoudi E: Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment. Anticancer Agents Med Chem. 12:707–717. 2012. View Article : Google Scholar : PubMed/NCBI
57	Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, Joshi BH and Puri RK: Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. PLoS One. 7:e344372012. View Article : Google Scholar : PubMed/NCBI
58	Tian J, Zhang R, Piao H, Li X, Sheng W, Zhou J, Dong M, Zhang X, Yan X, Shang W, et al: Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells. Mol Med Rep. 18:3280–3288. 2018.PubMed/NCBI
59	Hou FQ, Lei XF, Yao JL, Wang YJ and Zhang W: Tetraspanin 1 is involved in survival, proliferation and carcinogenesis of pancreatic cancer. Oncol Rep. 34:3068–3076. 2015. View Article : Google Scholar : PubMed/NCBI
60	Lupski JR, Gonzaga-Jauregui C, Yang Y, Bainbridge MN, Jhangiani S, Buhay CJ, Kovar CL, Wang M, Hawes AC, Reid JG, et al: Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing charcot-marie-tooth neuropathy. Genome Med. 5:572013. View Article : Google Scholar : PubMed/NCBI
61	Stendel C, Roos A, Kleine H, Arnaud E, Özçelik M, Sidiropoulos PN, Zenker J, Schüpfer F, Lehmann U, Sobota RM, et al: SH3TC2, a protein mutant in charcot-marie-tooth neuropathy, links peripheral nerve myelination to endosomal recycling. Brain. 133:2462–2474. 2010. View Article : Google Scholar : PubMed/NCBI PubMed/NCBI